#OncologyTrials
LightNews LightNews
oncodaily.bsky.social
START and OneOncology Partner to Expand Access to Early-Phase Oncology Trials

oncodaily.com/insight/star...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #START #OneOncology #Partnership #OncologyTrials
START and OneOncology Partner to Expand Access to Early-Phase Oncology Trials - OncoDaily
START and OneOncology Partner to Expand Access to Early-Phase Oncology Trials / Astera Cancer Care, Barry Russo, cancer, Cancer and Hematology Centers, CCBD,
oncodaily.com
May 29, 2025 at 8:10 PM
thecancersurvivorsclub.com
Important data from the LITESPARK-012 trial: while the triplet combo didn’t beat KEYTRUDA plus LENVIMA on primary endpoints, every result in science shapes what comes next for kidney cancer patients. www.merck.com/news/merck-a... #Carcinoma #OncologyTrials #KidneyCancer #ClinicalTrials #TCSC
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) - Merck.com
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treat...
www.merck.com
April 22, 2026 at 7:38 PM
gmj-georgia.bsky.social
🔬 Breakthrough in prostate cancer treatment: New triple-drug therapy shows 30% reduction in disease progression risk. Major NEJM…

#Androgentherapy #Metastaticcancer #Oncologytrials #PARPinhibitors #Prostatecancer

#Androgentherapy #Metastaticcancer #Oncologytrials #PARPinhibitors #Prostatecancer…
Triple Therapy Breakthrough for Prostate Cancer
🔬 Breakthrough in prostate cancer treatment: New triple-drug therapy shows 30% reduction in disease progression risk. Major NEJM… #Androgentherapy #Metastaticcancer #Oncologytrials #PARPinhibitors #Prostatecancer
news.gmj.ge
June 8, 2026 at 10:17 AM
gmj-georgia.bsky.social
🚨 BREAKING: New bispecific antibody zanidatamab shows 56% improvement in HER2+ gastric cancer survival vs standard treatme…

#Bispecificantibody #Gastroesophagealcancer #HER2positivecancer #Oncologytrials #Zanidatamab

#Bispecificantibody #Gastroesophagealcancer #HER2positivecancer #Oncologytrial…
New HER2 Drug Shows 56% Cancer Survival Improvement
🚨 BREAKING: New bispecific antibody zanidatamab shows 56% improvement in HER2+ gastric cancer survival vs standard treatme… #Bispecificantibody #Gastroesophagealcancer #HER2positivecancer #Oncologytrials #Zanidatamab
news.gmj.ge
May 28, 2026 at 6:05 PM
medbridgenz.bsky.social
Exploring options after standard cancer treatments fail? China hosts ~40% of global oncology trials, but international access requires passing strict paper-based pre-screening
Read guide: zurl.co/ujASs

#MedicalTourismChina #OncologyTrials #MedBridgeNZ #ClinicalResearch
Biomarker-Driven Oncology Trials in China | Pre-Screening
Exploring options after standard therapies fail? Learn how international patients navigate strict eligibility for biomarker-driven oncology trials in China.
zurl.co
July 1, 2026 at 9:00 PM